MVM V

VitalConnect specializes in developing wearable biosensor technology for continuous patient monitoring. The company designs adhesive patches that adhere to the body, enabling the real-time recording of vital signs. By integrating expertise in biomedical engineering, data analytics, and chip design, VitalConnect's products support healthcare professionals in various settings, including hospitals and post-discharge care. The data collected can be easily accessed via mobile devices or computer systems, allowing for immediate response to urgent situations and providing valuable insights into patient health. This technology aims to enhance decision-making processes in clinical environments and improve overall patient care.

GT Medical Technologies, Inc. is a medical device company based in Tempe, Arizona, dedicated to improving the lives of patients with brain tumors. Founded in 2017, the company has developed an innovative treatment approach through its flagship product, GammaTile, which combines a biocompatible, conformable collagen matrix with brachytherapy radiation seeds. This technology is designed to address the limitations of existing treatments for recurrent brain tumors, providing a bioresorbable solution that enhances treatment efficacy. GammaTile is protected by multiple patents and has the potential to benefit a significant patient population, with an estimated 176,000 patients diagnosed annually in the United States. To date, clinical trials at Barrow Neurological Institute have demonstrated promising outcomes, with significant clinical improvements observed in patients treated with this novel device.

Ossio is an orthopedic fixation company dedicated to enhancing the orthopedic experience for patients, healthcare providers, and payors. Established in 2014, the company focuses on developing innovative alternatives to traditional metal implants in the orthopedic fixation market, which is valued at over $10 billion. Their flagship product, OSSIOfiber, utilizes Intelligent Bone Regeneration Technology, offering a biocomposite material that is designed to support the natural healing process. This breakthrough platform allows for secure fixation while enabling the body to regenerate bone tissue, effectively replacing the implant without leaving any permanent material behind. Ossio's technology addresses the limitations of conventional bio-resorbable materials, providing the necessary mechanical strength for easy insertion and stable fixation, while promoting better healing outcomes for patients with orthopedic disorders.

Icotec specializes in the development and production of carbon fiber reinforced plastic implants for spine surgeries and treatments, focusing on enhancing stability and quality of life for patients with spinal tumors.

Nalu Medical is an early-stage company based in Carlsbad, California, specializing in the development of innovative medical devices aimed at alleviating chronic pain. Founded in 2014, the company has created a battery-free, micro-implantable pulse generator designed for neurostimulation, which has received FDA clearance for both spinal cord stimulation and peripheral nerve stimulation. By focusing on neuromodulation, Nalu Medical offers a diverse range of therapeutic options, enabling patients to receive effective treatments that improve their quality of life.

Gynesonics, Inc. is a medical device company that focuses on designing and developing minimally invasive solutions for symptomatic uterine fibroids in women. Established in 2005 and headquartered in Redwood City, California, with an additional location in Beuningen, the Netherlands, the company offers the Sonata System, which utilizes sonography-guided transcervical fibroid ablation for the treatment of fibroids under intrauterine sonography guidance. Gynesonics aims to provide a safe and effective incisionless alternative to traditional surgical techniques such as hysterectomy and myomectomy, thereby enabling women to receive painless treatments for severe menstrual symptoms associated with fibroids.

BioProtect Ltd. is an international medical device startup focused on developing and commercializing biodegradable balloon spacers designed to protect normal tissue during cancer radiation therapy. The company's flagship product, the ProSpace balloon spacer, has demonstrated superior efficacy and safety in safeguarding the rectum during radiation treatment for prostate cancer. This innovative technology significantly reduces the risk of serious and chronic side effects associated with radiation, while enhancing tumor control. Founded in 2004 and headquartered in Israel, BioProtect also operates subsidiaries in Germany and the United States, aiming to address unmet clinical needs in the growing radiotherapy spacers market with its platform of biodegradable implantable balloons.

CurvaFix, Inc. is a medical device company based in Bellevue, Washington, founded in 2017. The company focuses on developing innovative solutions for orthopedic trauma, specifically targeting pelvic fractures. Its flagship product, The CurvaFix, is an intramedullary rod screw designed to conform to the natural curvature of bones, effectively filling the space within curved structures such as the pelvis. By enabling surgeons to perform simpler and shorter procedures, CurvaFix aims to enhance patient recovery outcomes in the treatment of pelvic injuries.

eXmoor Pharma is a consultancy focused on cell and gene therapies, as well as biopharmaceuticals. The company operates a contract development and manufacturing business that provides a variety of services tailored to the needs of its clients. These services include manufacturing strategy, process development consultancy, and bioprocess engineering. By leveraging its expertise, eXmoor Pharma helps organizations design and implement projects that align with their specific goals and commercial objectives in the rapidly evolving field of advanced therapy medicinal products (ATMPs).

GT Medical Technologies, Inc. is a medical device company based in Tempe, Arizona, dedicated to improving the lives of patients with brain tumors. Founded in 2017, the company has developed an innovative treatment approach through its flagship product, GammaTile, which combines a biocompatible, conformable collagen matrix with brachytherapy radiation seeds. This technology is designed to address the limitations of existing treatments for recurrent brain tumors, providing a bioresorbable solution that enhances treatment efficacy. GammaTile is protected by multiple patents and has the potential to benefit a significant patient population, with an estimated 176,000 patients diagnosed annually in the United States. To date, clinical trials at Barrow Neurological Institute have demonstrated promising outcomes, with significant clinical improvements observed in patients treated with this novel device.

Ossio is an orthopedic fixation company dedicated to enhancing the orthopedic experience for patients, healthcare providers, and payors. Established in 2014, the company focuses on developing innovative alternatives to traditional metal implants in the orthopedic fixation market, which is valued at over $10 billion. Their flagship product, OSSIOfiber, utilizes Intelligent Bone Regeneration Technology, offering a biocomposite material that is designed to support the natural healing process. This breakthrough platform allows for secure fixation while enabling the body to regenerate bone tissue, effectively replacing the implant without leaving any permanent material behind. Ossio's technology addresses the limitations of conventional bio-resorbable materials, providing the necessary mechanical strength for easy insertion and stable fixation, while promoting better healing outcomes for patients with orthopedic disorders.

Neurolens is a company that specializes in prescription lenses designed to alleviate discomfort caused by eye misalignment. Founded in 2012 and based in Costa Mesa, California, Neurolens incorporates a contoured prism into its lenses to improve eye alignment, which can help relieve headaches, neck and shoulder pain, and eyestrain. The company has developed a vision measurement device that utilizes an eye-tracking system capable of detecting even minor misalignments, measured in prism diopters. This innovative approach aims to address the chronic discomfort many individuals experience due to prolonged use of digital devices, reading, or engaging in detailed work.

Nalu Medical is an early-stage company based in Carlsbad, California, specializing in the development of innovative medical devices aimed at alleviating chronic pain. Founded in 2014, the company has created a battery-free, micro-implantable pulse generator designed for neurostimulation, which has received FDA clearance for both spinal cord stimulation and peripheral nerve stimulation. By focusing on neuromodulation, Nalu Medical offers a diverse range of therapeutic options, enabling patients to receive effective treatments that improve their quality of life.

VERO Biotech LLC is a development stage biopharmaceutical company based in Atlanta, Georgia, focused on creating innovative solutions for patients with pulmonary and cardiac diseases. The company specializes in the design, development, and commercialization of inhaled nitric oxide (NO) products, utilizing its GeNOsyl drug delivery technology. This technology comprises a single-use drug cassette paired with either a portable console or a wearable controller, facilitating the safe delivery of NO for various therapeutic applications. VERO Biotech is developing GeNOsyl Acute DS for acute vasoreactivity testing in patients with pulmonary arterial hypertension (PAH) and for treating pulmonary hypertension in post-surgical patients and newborns with hypoxic respiratory failure. Additionally, it is working on GeNOsyl Chronic DS for managing PAH and pulmonary hypertension associated with idiopathic pulmonary fibrosis. By providing user-friendly and portable NO delivery systems, VERO Biotech aims to improve clinical workflows and address the unmet medical needs in these patient populations.

Inbrace is a medical device company focused on innovative orthodontic solutions. Its flagship product, INBRACE, is a discreet alignment system that is placed behind the teeth, utilizing patented self-guiding technology to apply continuous forces for gentle correction of dental alignment. This approach significantly reduces pain and minimizes the number of required visits to the orthodontist, addressing common patient concerns and enhancing satisfaction. INBRACE is FDA registered and aims to expand access to orthodontic treatment, thereby driving practice growth for dental professionals. The company's platform incorporates digital treatment planning, computer modeling, and direct digital manufacturing, allowing for customized solutions that maintain high standards of care across various orthodontic cases.

eXmoor Pharma is a consultancy focused on cell and gene therapies, as well as biopharmaceuticals. The company operates a contract development and manufacturing business that provides a variety of services tailored to the needs of its clients. These services include manufacturing strategy, process development consultancy, and bioprocess engineering. By leveraging its expertise, eXmoor Pharma helps organizations design and implement projects that align with their specific goals and commercial objectives in the rapidly evolving field of advanced therapy medicinal products (ATMPs).

GT Medical Technologies, Inc. is a medical device company based in Tempe, Arizona, dedicated to improving the lives of patients with brain tumors. Founded in 2017, the company has developed an innovative treatment approach through its flagship product, GammaTile, which combines a biocompatible, conformable collagen matrix with brachytherapy radiation seeds. This technology is designed to address the limitations of existing treatments for recurrent brain tumors, providing a bioresorbable solution that enhances treatment efficacy. GammaTile is protected by multiple patents and has the potential to benefit a significant patient population, with an estimated 176,000 patients diagnosed annually in the United States. To date, clinical trials at Barrow Neurological Institute have demonstrated promising outcomes, with significant clinical improvements observed in patients treated with this novel device.

Paragon 28, Inc. is a medical device company specializing in products for foot and ankle surgery. Incorporated in 2010 and based in Englewood, Colorado, with an additional headquarters in Dublin, Ireland, the company offers a comprehensive range of surgical solutions, including plates, screws, allograft bone systems, and interference screws for various orthopedic procedures. Its product portfolio features advanced systems such as the PHANTOM Lapidus Intramedullary Nail for arthrodesis correction, the Proximal Rotational Metatarsal Osteotomy for bunion correction, and the Paratrooper Plantar Plate Repair System for plantar plate repairs. Paragon 28 aims to meet the diverse needs of foot and ankle surgeries through its nearly 80 product systems, addressing conditions such as hallux valgus, fracture fixation, and flat foot. The company primarily generates revenue from the United States market.

SkyCell AG specializes in designing and manufacturing temperature-controlled containers tailored for the pharmaceutical industry. Founded in 2013 and headquartered in Zurich, Switzerland, the company focuses on ensuring the safe transport of temperature-sensitive goods. Its product lineup includes various models such as SkyCell 2500C, SkyCell 2500CRT, SkyCell 1500C, SkyCell 1500CRT, SkyCell 770C, and SkyCell 770CRT. Equipped with Internet of Things (IoT) sensors, these containers connect to SkyCell's data cloud, enabling real-time monitoring and intervention to prevent temperature excursions. Additionally, the company's software leverages blockchain technology to enhance tracking and visibility throughout the supply chain. SkyCell is committed to sustainability and reducing carbon emissions while addressing logistical challenges faced by global pharmaceutical companies.

MDxHealth is a molecular diagnostics company focused on developing and commercializing advanced epigenetic tests to assist in the detection and treatment of cancer. The company's product portfolio includes ConfirmMDx, a prostate cancer test aimed at addressing false-negative biopsy concerns; SelectMDx, which guides repeat biopsies for prostate cancer; AssureMDx, a noninvasive liquid biopsy test for bladder cancer; and PredictMDx for Glioblastoma, a tissue methylation test that aids in treatment decisions for brain cancer. Established in 2003 and headquartered in Irvine, California, with additional offices in Belgium and the Netherlands, MDxHealth leverages proprietary genomic and epigenetic technologies to provide actionable diagnostic information. The company's revenue is generated through clinical laboratory services and out-licensing of its patented DNA methylation platform and biomarkers, serving markets primarily in the United States and Europe.

Providence Medical Technology is a medical device company dedicated to developing innovative solutions for cervical spine conditions in the United States and internationally. The company specializes in the design of surgical instrumentation and implants that address cervical degenerative disc disease through a unique approach to indirect decompression and fusion. Its primary offerings include the DTRAX Spinal System, which consists of single-use disposable instruments for accessing the spine via posterior incisions, and the DTRAX Cervical Cage, designed to treat cervical radiculopathy by facilitating indirect decompression and fusion. Additionally, the company provides the DTRAX Graft, a structural allograft for posterior fusion support, and the DTRAX Facet System, a sterile kit containing necessary tools and implants for single-level surgeries. Providence Medical Technology distributes its products through a network of distributors and sales representatives and is headquartered in Lafayette, California.

Zipline Medical, Inc. is a healthcare company specializing in the development and commercialization of non-invasive skin closure solutions. Founded in 2009 and based in Campbell, California, the company focuses on its innovative PRELOC™ technology platform, which provides uniform closure forces while minimizing tension that can lead to scarring. The flagship product, Zip Surgical Skin Closure, is applicable across a range of medical specialties, including cardiology, orthopedics, dermatology, and emergency medicine. The technology aims to combine the speed of staples with the cosmetic advantages of sutures, addressing the clinical need for rapid and effective skin closure while reducing the risk of surgical site infections. By eliminating skin punctures and decreasing the risk of needlestick injuries, Zipline Medical enhances surgical outcomes and patient care in various surgical procedures. The company operates as a subsidiary of Stryker Corporation.

VitalConnect specializes in developing wearable biosensor technology for continuous patient monitoring. The company designs adhesive patches that adhere to the body, enabling the real-time recording of vital signs. By integrating expertise in biomedical engineering, data analytics, and chip design, VitalConnect's products support healthcare professionals in various settings, including hospitals and post-discharge care. The data collected can be easily accessed via mobile devices or computer systems, allowing for immediate response to urgent situations and providing valuable insights into patient health. This technology aims to enhance decision-making processes in clinical environments and improve overall patient care.

Cheetah Medical, Inc. is a medical technology company specializing in the development and commercialization of non-invasive solutions for monitoring cardiac output and hemodynamics. Its flagship product, the CHEETAH NICOM system, is a non-invasive cardiac output monitor that aids in clinical applications such as fluid optimization, hemodynamic diagnosis, and drug titration. The system provides valuable insights into conditions like hypovolemic shock, septic shock, and acute renal failure, among others. CE marked and FDA cleared, the CHEETAH NICOM is recognized for its equivalence to invasive monitoring systems. Cheetah Medical distributes its products to medical centers across numerous countries, including the United States, Australia, and several European and Asian nations. Founded in 2000 and headquartered in Newton Center, Massachusetts, Cheetah Medical also maintains offices in Vancouver, Washington, Tel Aviv, Israel, and the United Kingdom, and operates as a subsidiary of Baxter International Inc. The company remains dedicated to research and development, collaborating closely with clinicians to enhance patient outcomes.

Vertos Medical Inc. is a medical device company specializing in minimally invasive treatments for lumbar spinal stenosis (LSS). Founded in 2005 and headquartered in Aliso Viejo, California, the company has developed the mild device, which provides an outpatient, fluoroscopically guided treatment for LSS without the need for implants. This innovative approach allows physicians to perform lumbar decompression procedures under local anesthesia, helping to restore space in the spinal canal, alleviate pressure on nerves, and enhance patient mobility. Vertos Medical's commitment to advancing spinal care is reflected in its focus on delivering effective solutions for common spinal diseases.

Zipline Medical, Inc. is a healthcare company specializing in the development and commercialization of non-invasive skin closure solutions. Founded in 2009 and based in Campbell, California, the company focuses on its innovative PRELOC™ technology platform, which provides uniform closure forces while minimizing tension that can lead to scarring. The flagship product, Zip Surgical Skin Closure, is applicable across a range of medical specialties, including cardiology, orthopedics, dermatology, and emergency medicine. The technology aims to combine the speed of staples with the cosmetic advantages of sutures, addressing the clinical need for rapid and effective skin closure while reducing the risk of surgical site infections. By eliminating skin punctures and decreasing the risk of needlestick injuries, Zipline Medical enhances surgical outcomes and patient care in various surgical procedures. The company operates as a subsidiary of Stryker Corporation.

Valneva is a biopharmaceutical company specializing in the development, manufacturing, and distribution of prophylactic vaccines for infectious diseases. Its portfolio comprises two commercially available vaccines (IXIARO/JESPECT for Japanese encephalitis and DUKORAL for traveler's diarrhea), along with vaccine candidates targeting Lyme disease, chikungunya virus, and COVID-19. Valneva operates through segments including Commercialized Vaccines, Covid-19 Vaccine, Vaccine Candidates, and Technologies & Services. The company aims to address significant unmet medical needs in infectious diseases by leveraging its expertise and capabilities to advance vaccine candidates through clinical trials and ultimately commercialize them.

Providence Medical Technology is a medical device company dedicated to developing innovative solutions for cervical spine conditions in the United States and internationally. The company specializes in the design of surgical instrumentation and implants that address cervical degenerative disc disease through a unique approach to indirect decompression and fusion. Its primary offerings include the DTRAX Spinal System, which consists of single-use disposable instruments for accessing the spine via posterior incisions, and the DTRAX Cervical Cage, designed to treat cervical radiculopathy by facilitating indirect decompression and fusion. Additionally, the company provides the DTRAX Graft, a structural allograft for posterior fusion support, and the DTRAX Facet System, a sterile kit containing necessary tools and implants for single-level surgeries. Providence Medical Technology distributes its products through a network of distributors and sales representatives and is headquartered in Lafayette, California.

Biotheranostics, Inc. is a commercial-stage molecular diagnostics company based in San Diego, California, focused on developing and providing proprietary diagnostic, prognostic, and predictive tests to support cancer treatment. The company offers a range of tests, including the Breast Cancer Index, which assists oncologists in making informed decisions about extended endocrine therapy for estrogen receptor-positive breast cancer patients. Additionally, CancerTYPE ID provides genomic information crucial for the diagnosis and treatment of metastatic cancer, while the bioT3 metastatic cancer solution integrates molecular diagnosis with comprehensive biomarker data to enhance treatment options for metastatic cancer patients. Biotheranostics operates a CLIA-certified, CAP-accredited laboratory, which is authorized to perform testing across all 50 states, positioning the company as a leader in addressing unmet medical needs in oncology. Founded in 1996, Biotheranostics was previously known as AviaraDx, Inc. and rebranded in 2008.

Zipline Medical, Inc. is a healthcare company specializing in the development and commercialization of non-invasive skin closure solutions. Founded in 2009 and based in Campbell, California, the company focuses on its innovative PRELOC™ technology platform, which provides uniform closure forces while minimizing tension that can lead to scarring. The flagship product, Zip Surgical Skin Closure, is applicable across a range of medical specialties, including cardiology, orthopedics, dermatology, and emergency medicine. The technology aims to combine the speed of staples with the cosmetic advantages of sutures, addressing the clinical need for rapid and effective skin closure while reducing the risk of surgical site infections. By eliminating skin punctures and decreasing the risk of needlestick injuries, Zipline Medical enhances surgical outcomes and patient care in various surgical procedures. The company operates as a subsidiary of Stryker Corporation.

Onbone Oy is a Finnish medical technology company based in Helsinki, specializing in the development and marketing of innovative Woodcast products designed for orthopedic and traumatology applications. The Woodcast product line includes various items such as ribbons, colored splints, folded splints, and heating devices, which are aimed at improving patient care and treatment outcomes. The company distributes its products through local distributors in multiple countries, including Finland, Germany, Sweden, the Netherlands, and Great Britain. Established in 2008, Onbone Oy was previously known as Injectobone Finland Oy before rebranding in January 2010. With a dedicated team of eleven employees, Onbone focuses on providing user-friendly solutions in the medical technology sector.

AmbioPharm, Inc. is a contract manufacturer specializing in peptides and biopharmaceuticals for the pharmaceutical and biotech sectors. Founded in 2006, the company is based in North Augusta, South Carolina, with additional manufacturing facilities in Shanghai, China. AmbioPharm focuses on the development and production of peptide active pharmaceutical ingredients (APIs), including generic peptides and custom formulations, for pre-clinical and clinical applications. Their services encompass GLP-grade peptides, non-peptidic small molecules, and conjugations to various compounds, all produced under current Good Manufacturing Practices (cGMP). The company supports a wide range of clinical studies across multiple therapeutic areas, including oncology, neurology, and infectious diseases. By employing a responsive business model and efficient manufacturing processes, AmbioPharm enables clients to advance their peptide projects from preclinical stages to commercial readiness in a cost-effective manner.

Vascular Pathways is a privately held medical device company founded by Amir Belson, M.D. The company specializes in the commercialization of its flagship product, the Rapid IntraVascular Start (RIVS) catheter. This FDA-cleared device is designed to facilitate rapid, safe, and successful peripheral intravenous (IV) insertion, addressing a critical need in medical settings. By streamlining the process of IV placement, Vascular Pathways aims to enhance patient care and improve outcomes in various healthcare environments.

Tarsa Therapeutics, Inc. is focused on developing therapies for the treatment and prevention of osteoporosis and related bone diseases, particularly in postmenopausal women. The company is advancing TBRIA, an oral formulation of salmon calcitonin, which aims to slow the rate of bone destruction associated with osteoporosis. Tarsa Therapeutics provides clinical programs that address both the treatment and prevention of osteoporosis, specifically targeting women who are more than five years post-menopause and may not be suitable for alternative therapies. Founded in 2009 and based in Philadelphia, Pennsylvania, Tarsa Therapeutics was previously known as Boneco, Inc.

Wilson Therapeutics is a biopharmaceutical company located in Stockholm, Sweden, focusing on the development of innovative therapies for rare diseases, particularly Wilson Disease. The company’s primary product, Decuprate®, is being investigated as a new treatment option for this condition and is currently undergoing evaluation in a Phase II clinical study involving patients with Wilson Disease. By targeting copper-mediated disorders, Wilson Therapeutics aims to address unmet medical needs in this specialized area of healthcare.

Cheetah Medical, Inc. is a medical technology company specializing in the development and commercialization of non-invasive solutions for monitoring cardiac output and hemodynamics. Its flagship product, the CHEETAH NICOM system, is a non-invasive cardiac output monitor that aids in clinical applications such as fluid optimization, hemodynamic diagnosis, and drug titration. The system provides valuable insights into conditions like hypovolemic shock, septic shock, and acute renal failure, among others. CE marked and FDA cleared, the CHEETAH NICOM is recognized for its equivalence to invasive monitoring systems. Cheetah Medical distributes its products to medical centers across numerous countries, including the United States, Australia, and several European and Asian nations. Founded in 2000 and headquartered in Newton Center, Massachusetts, Cheetah Medical also maintains offices in Vancouver, Washington, Tel Aviv, Israel, and the United Kingdom, and operates as a subsidiary of Baxter International Inc. The company remains dedicated to research and development, collaborating closely with clinicians to enhance patient outcomes.

Horizon Discovery Group plc is a UK-based life science company specializing in gene editing and gene modulation technologies that advance research and clinical applications in human health. Established in 2007 and headquartered in Cambridge, the company designs, manufactures, and applies a wide array of gene editing tools, including custom-made and off-the-shelf RNA interference (RNAi) reagents, CRISPR reagents, and various cell models. Horizon Discovery offers services such as pooled and arrayed CRISPR screens, drug screens, and immunology assays, catering to the needs of academic research labs, biopharmaceutical companies, and contract research organizations. Its extensive product catalog includes over 1,000,000 cell and reagent products that help scientists investigate genetic anomalies associated with diseases like cancer. The company has formed strategic partnerships with various institutions to enhance its offerings, including collaborations for developing innovative gene editing technologies. As of December 2020, Horizon operates as a subsidiary of PerkinElmer (UK) Holdings Ltd.

Cheetah Medical, Inc. is a medical technology company specializing in the development and commercialization of non-invasive solutions for monitoring cardiac output and hemodynamics. Its flagship product, the CHEETAH NICOM system, is a non-invasive cardiac output monitor that aids in clinical applications such as fluid optimization, hemodynamic diagnosis, and drug titration. The system provides valuable insights into conditions like hypovolemic shock, septic shock, and acute renal failure, among others. CE marked and FDA cleared, the CHEETAH NICOM is recognized for its equivalence to invasive monitoring systems. Cheetah Medical distributes its products to medical centers across numerous countries, including the United States, Australia, and several European and Asian nations. Founded in 2000 and headquartered in Newton Center, Massachusetts, Cheetah Medical also maintains offices in Vancouver, Washington, Tel Aviv, Israel, and the United Kingdom, and operates as a subsidiary of Baxter International Inc. The company remains dedicated to research and development, collaborating closely with clinicians to enhance patient outcomes.

eZono AG is a company based in Jena, Germany, that specializes in designing, developing, and marketing tablet ultrasound systems. Established in 2004, eZono focuses on point-of-care solutions, offering products such as the eZono 4000 and eZono 3000, which provide portable ultrasound capabilities for use in various clinical settings, including anesthesiology, pain management, and emergency medicine. The company also features eZGuide, a needle guidance technology that enhances visualization of needle tracks, along with Cue Cards that serve as a reference library for clinical procedures. eZono's innovative approach empowers non-traditional ultrasound users to integrate sonography into their practice, ultimately aiming to improve clinical outcomes, enhance patient satisfaction, and reduce costs. The company serves a global customer base while promoting a diverse and dynamic team dedicated to advancing ultrasound technology.

Cara Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Stamford, Connecticut, specializing in the development and commercialization of innovative therapeutics for pain and pruritus. The company primarily focuses on its lead product candidate, CR845 (difelikefalin), which is designed to selectively target kappa opioid receptors and is currently undergoing Phase III clinical trials for treating moderate-to-severe chronic kidney disease-associated pruritus in patients undergoing hemodialysis. Cara is also advancing Oral KORSUVA, which has completed Phase II trials for pruritus in chronic kidney disease and is in trials for pruritus associated with chronic liver disease and atopic dermatitis. Furthermore, the company is developing CR845/difelikefalin Injection for acute postoperative pain, having completed Phase II/III trials. Cara Therapeutics collaborates with Maruishi Pharmaceutical Co., Ltd. and Chong Kun Dang Pharmaceutical Corporation for the development and commercialization of its product candidates in Japan and South Korea, respectively. Founded in 2004, Cara Therapeutics aims to leverage its proprietary drug screening technology to create a pipeline of first-in-class therapeutics.

Tarsa Therapeutics, Inc. is focused on developing therapies for the treatment and prevention of osteoporosis and related bone diseases, particularly in postmenopausal women. The company is advancing TBRIA, an oral formulation of salmon calcitonin, which aims to slow the rate of bone destruction associated with osteoporosis. Tarsa Therapeutics provides clinical programs that address both the treatment and prevention of osteoporosis, specifically targeting women who are more than five years post-menopause and may not be suitable for alternative therapies. Founded in 2009 and based in Philadelphia, Pennsylvania, Tarsa Therapeutics was previously known as Boneco, Inc.

Patient Connect operates a clinical information platform focused on delivering evidence-based clinical messages at the point of care. By providing patient support and education, the platform enhances patient understanding of medication importance, proper usage, and management of side effects, thereby improving compliance. The company has established itself as a pioneer in clinical messaging services, reaching 40% of retail pharmacies and 50% of hospital pharmacies. Over the past three years, Patient Connect has successfully completed more than 40 customer projects for 18 of the top 20 pharmaceutical companies in the UK, solidifying its reputation in the healthcare sector.

Horizon Discovery Group plc is a UK-based life science company specializing in gene editing and gene modulation technologies that advance research and clinical applications in human health. Established in 2007 and headquartered in Cambridge, the company designs, manufactures, and applies a wide array of gene editing tools, including custom-made and off-the-shelf RNA interference (RNAi) reagents, CRISPR reagents, and various cell models. Horizon Discovery offers services such as pooled and arrayed CRISPR screens, drug screens, and immunology assays, catering to the needs of academic research labs, biopharmaceutical companies, and contract research organizations. Its extensive product catalog includes over 1,000,000 cell and reagent products that help scientists investigate genetic anomalies associated with diseases like cancer. The company has formed strategic partnerships with various institutions to enhance its offerings, including collaborations for developing innovative gene editing technologies. As of December 2020, Horizon operates as a subsidiary of PerkinElmer (UK) Holdings Ltd.

Beacon Endoscopic is a Boston-based medical device company focused on innovating interventional endoscopic procedures. The company specializes in the development of advanced products for upper gastrointestinal and bronchial endoscopy markets, aiming to enhance existing surgical techniques and create next-generation devices that improve patient outcomes and change the approach to surgery.

AccuVein Inc. is a manufacturer of vein visualization solutions aimed at enhancing clinical care for healthcare professionals. Founded in 2006 and based in Medford, New York, the company specializes in portable, non-contact devices that enable practitioners to visualize peripheral veins on a patient's skin. Its flagship product, the AV400, utilizes proprietary technology to assist in locating veins for various medical procedures, including IV access, blood draws, and cosmetic injections. AccuVein also offers a range of products, including hands-free and wheeled solutions, to cater to different medical settings such as surgery centers, imaging centers, and long-term care facilities. The company's products are distributed through a network of sales representatives and distributors both domestically and internationally.

Vantia Ltd is a pharmaceutical company based in Southampton, United Kingdom, focused on developing small molecule drugs that address significant unmet medical needs. Established in 2007, the company has a clinical pipeline that includes VA106483, aimed at treating nocturia, a condition that disrupts sleep due to frequent nighttime urination, and VA111913, designed for dysmenorrhea, which involves painful menstrual cramps caused by abnormal uterine contractions. These conditions affect millions of individuals and represent substantial market opportunities. Vantia's strategy involves advancing its proprietary drug candidates through Phase II clinical testing and seeking commercialization through partnerships, positioning itself to make a meaningful impact in the urology and women's health sectors.

Lombard Medical, Inc. is a medical technology company that specializes in developing, manufacturing, and marketing endovascular stent-grafts for the repair of aortic aneurysms. Its principal product, Aorfix, is designed to treat abdominal aortic aneurysms (AAAs) in patients with neck angulations of up to 90 degrees. The company's product portfolio also includes the Altura endovascular stent-graft system for standard AAA anatomies, and advanced delivery systems like Aorflex and IntelliFlex LP, which enhance the precision of stent-graft deployment. Lombard Medical markets its products through a direct sales force and distributors, primarily targeting state- or government-owned hospitals. Established in 2000 and headquartered in Didcot, the United Kingdom, Lombard Medical serves various international markets, with a significant portion of its revenue derived from Japan.

Vascular Pathways is a privately held medical device company founded by Amir Belson, M.D. The company specializes in the commercialization of its flagship product, the Rapid IntraVascular Start (RIVS) catheter. This FDA-cleared device is designed to facilitate rapid, safe, and successful peripheral intravenous (IV) insertion, addressing a critical need in medical settings. By streamlining the process of IV placement, Vascular Pathways aims to enhance patient care and improve outcomes in various healthcare environments.

SOLX, Inc. is a Waltham, Massachusetts-based company that specializes in developing devices and treatments for glaucoma therapy. Founded in 2000, the company focuses on creating innovative solutions to reduce, manage, and measure intraocular pressure (IOP) in the human eye. One of its key offerings is the SOLX Gold Shunt, a minimally invasive device designed for the surgical treatment of glaucoma. Through its product portfolio, SOLX aims to improve patient outcomes in glaucoma management.

Cara Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Stamford, Connecticut, specializing in the development and commercialization of innovative therapeutics for pain and pruritus. The company primarily focuses on its lead product candidate, CR845 (difelikefalin), which is designed to selectively target kappa opioid receptors and is currently undergoing Phase III clinical trials for treating moderate-to-severe chronic kidney disease-associated pruritus in patients undergoing hemodialysis. Cara is also advancing Oral KORSUVA, which has completed Phase II trials for pruritus in chronic kidney disease and is in trials for pruritus associated with chronic liver disease and atopic dermatitis. Furthermore, the company is developing CR845/difelikefalin Injection for acute postoperative pain, having completed Phase II/III trials. Cara Therapeutics collaborates with Maruishi Pharmaceutical Co., Ltd. and Chong Kun Dang Pharmaceutical Corporation for the development and commercialization of its product candidates in Japan and South Korea, respectively. Founded in 2004, Cara Therapeutics aims to leverage its proprietary drug screening technology to create a pipeline of first-in-class therapeutics.

Cheetah Medical, Inc. is a medical technology company specializing in the development and commercialization of non-invasive solutions for monitoring cardiac output and hemodynamics. Its flagship product, the CHEETAH NICOM system, is a non-invasive cardiac output monitor that aids in clinical applications such as fluid optimization, hemodynamic diagnosis, and drug titration. The system provides valuable insights into conditions like hypovolemic shock, septic shock, and acute renal failure, among others. CE marked and FDA cleared, the CHEETAH NICOM is recognized for its equivalence to invasive monitoring systems. Cheetah Medical distributes its products to medical centers across numerous countries, including the United States, Australia, and several European and Asian nations. Founded in 2000 and headquartered in Newton Center, Massachusetts, Cheetah Medical also maintains offices in Vancouver, Washington, Tel Aviv, Israel, and the United Kingdom, and operates as a subsidiary of Baxter International Inc. The company remains dedicated to research and development, collaborating closely with clinicians to enhance patient outcomes.

Tarsa Therapeutics, Inc. is focused on developing therapies for the treatment and prevention of osteoporosis and related bone diseases, particularly in postmenopausal women. The company is advancing TBRIA, an oral formulation of salmon calcitonin, which aims to slow the rate of bone destruction associated with osteoporosis. Tarsa Therapeutics provides clinical programs that address both the treatment and prevention of osteoporosis, specifically targeting women who are more than five years post-menopause and may not be suitable for alternative therapies. Founded in 2009 and based in Philadelphia, Pennsylvania, Tarsa Therapeutics was previously known as Boneco, Inc.

Clavis Pharma ASA, a healthcare and clinical-stage pharmaceutical company, engages in the discovery and development of novel small molecule therapeutics for cancer and other unmet medical needs. It also engages in the development of new and improved pharmaceuticals based on its lipid vector technology (LVT). The company has three anti-cancer drugs in clinical development for various indications, and a pipeline of other drug candidates within oncology, virology, and anti-inflammatory diseases. Its products primarily include Elacytarabine, which is in the Phase II clinical trials for various solid tumor indications, as well as in Phase I/II clinical trials for the treatment of blood cancers, including leukemia; Intravenous CP-4126, a multicentre trial open to patients with any type of solid tumours that is in Phase I clinical trials; Oral CP-4126, an analogue of gemcitabine, which is Phase I clinical trial; and CP-4200, an epigenetic modulator that is in preclinical stage for the treatment of hematological malignancies, such as MDS and leukemia. The company�s products also include CP-4010, an analogue of acyclovir that is in the Phase I clinical trial for the treatment of herpes labialis and herpes genitalis; and CP-4018, an analogue of gancyclovir, which is in the preclinical stage. In addition, its products comprise CP-4033, CP-4112, and CP-4114 that are the analogues of ribavirin, betamethason, and prednisolon respectively. The company has a collaboration agreement with Mount Sinai School of Medicine for the design and testing of new LVT based drug candidates for the treatment of cancer and haematological malignancies. Clavis Pharma ASA was founded in 2001 and is headquartered in Oslo, Norway.

BioVex is a biotechnology company dedicated to developing and commercializing biological therapies for cancer treatment and the prevention of infectious diseases. Its primary focus is OncoVEXGM-CSF, an oncolytic vaccine that selectively targets and destroys cancer cells while sparing surrounding healthy tissue. This vaccine operates by replicating within solid tumors, leading to cancer cell death, and also stimulates a robust systemic immune response against tumors. OncoVEXGM-CSF has undergone clinical testing in over 110 patients across various solid tumors, including melanoma, head and neck cancer, breast cancer, and pancreatic cancer. The treatment has demonstrated significant efficacy, routinely eliminating tumors at the injection site and achieving overall disease responses during Phase II trials, with no reported recurrences of resolved tumors. Additionally, BioVex is developing ImmunoVEXHSV2, a vaccine aimed at preventing genital herpes.

Heptares Therapeutics Ltd. is a clinical-stage drug discovery company based in Welwyn Garden City, United Kingdom, founded in 2007. It specializes in developing novel small-molecule medicines that target G protein-coupled receptors (GPCRs), a significant family of druggable targets associated with various human diseases. Heptares has pioneered a proprietary technology that enables the creation of purified, stabilized, and functional GPCRs, known as StaRs (Stabilised Receptors), which addresses key challenges in the drug development process. The company offers a range of services including GPCR structure-based drug design, X-ray crystallography, surface plasmon resonance, fragment screening, and antibody discovery. Heptares has established strategic partnerships with several organizations, including Pfizer Inc., Kymab Limited, PeptiDream Inc., and Jitsubo Co., Ltd., to enhance its research and development capabilities. As of 2015, Heptares operates as a subsidiary of Sosei Group Corporation.

Serentis develops medical products and drugs. Its products include SRD441, a novel compound that targets endogenous pro-inflammatory and staphylococcus aureus-derived proteases; and SRD174, a topical product designed to produce relief of pruritus. The company’s research programs include SRD326, a topically-applied product for relief from symptoms of Raynaud’s phenomenon; and SRD285 which provides an approach to wound care, promoting enhanced wound healing and local analgesia. Serentis was founded in 2006 and is based in Cambridge, United Kingdom.

PregLem is a Swiss-based biopharmaceutical company focused on the development and commercialization of innovative drugs specifically for women's reproductive health. The company aims to address unmet medical needs in this field by creating advanced therapies that enhance the quality of care for women. Through its specialized approach, PregLem is committed to improving treatment options and outcomes for various reproductive health conditions.

Heptares Therapeutics Ltd. is a clinical-stage drug discovery company based in Welwyn Garden City, United Kingdom, founded in 2007. It specializes in developing novel small-molecule medicines that target G protein-coupled receptors (GPCRs), a significant family of druggable targets associated with various human diseases. Heptares has pioneered a proprietary technology that enables the creation of purified, stabilized, and functional GPCRs, known as StaRs (Stabilised Receptors), which addresses key challenges in the drug development process. The company offers a range of services including GPCR structure-based drug design, X-ray crystallography, surface plasmon resonance, fragment screening, and antibody discovery. Heptares has established strategic partnerships with several organizations, including Pfizer Inc., Kymab Limited, PeptiDream Inc., and Jitsubo Co., Ltd., to enhance its research and development capabilities. As of 2015, Heptares operates as a subsidiary of Sosei Group Corporation.

Serentis develops medical products and drugs. Its products include SRD441, a novel compound that targets endogenous pro-inflammatory and staphylococcus aureus-derived proteases; and SRD174, a topical product designed to produce relief of pruritus. The company’s research programs include SRD326, a topically-applied product for relief from symptoms of Raynaud’s phenomenon; and SRD285 which provides an approach to wound care, promoting enhanced wound healing and local analgesia. Serentis was founded in 2006 and is based in Cambridge, United Kingdom.

PregLem is a Swiss-based biopharmaceutical company focused on the development and commercialization of innovative drugs specifically for women's reproductive health. The company aims to address unmet medical needs in this field by creating advanced therapies that enhance the quality of care for women. Through its specialized approach, PregLem is committed to improving treatment options and outcomes for various reproductive health conditions.

Cara Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Stamford, Connecticut, specializing in the development and commercialization of innovative therapeutics for pain and pruritus. The company primarily focuses on its lead product candidate, CR845 (difelikefalin), which is designed to selectively target kappa opioid receptors and is currently undergoing Phase III clinical trials for treating moderate-to-severe chronic kidney disease-associated pruritus in patients undergoing hemodialysis. Cara is also advancing Oral KORSUVA, which has completed Phase II trials for pruritus in chronic kidney disease and is in trials for pruritus associated with chronic liver disease and atopic dermatitis. Furthermore, the company is developing CR845/difelikefalin Injection for acute postoperative pain, having completed Phase II/III trials. Cara Therapeutics collaborates with Maruishi Pharmaceutical Co., Ltd. and Chong Kun Dang Pharmaceutical Corporation for the development and commercialization of its product candidates in Japan and South Korea, respectively. Founded in 2004, Cara Therapeutics aims to leverage its proprietary drug screening technology to create a pipeline of first-in-class therapeutics.

Aegerion Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of therapeutics for cardiovascular and metabolic diseases. Headquartered in Bridgewater, New Jersey, Aegerion specializes in therapies for hyperlipidemia, aiming to address high levels of fat particles in the blood. The company's notable product, lomitapide, is a small molecule drug that acts as a microsomal triglyceride transfer protein inhibitor, designed to lower serum lipids, including cholesterol and triglycerides. Aegerion's efforts are directed towards treating conditions such as atherosclerosis, dyslipidemia, obesity, and pancreatitis, thereby enabling healthcare professionals to effectively manage debilitating diseases associated with these metabolic disorders. The company was incorporated in 2005.

BioXell was founded in 2002 as a spinout of Roche Milano Ricerche, a leading biomedical research institute created ten years earlier that focused on chronic inflammatory disease and autoimmunity. The idea to create BioXell originated with Francesco Sinigaglia, founder and director of the Milan-based research institute, following a scientific career path that took him to the University College in London, the Basel Institute of Immunology and the Hoffmann-La Roche research units in Basel. Dr. Sinigaglia, former CEO, approached Roche with his challenging project and a year later BioXell was spun off, with $22m invested by MPM Capital, Index Ventures and Life Science Partners.

Astrodyne TDI Corporation specializes in the development and manufacturing of power solutions, including AC/DC power supplies, DC/DC converters, LED drivers, and medical power supplies. The company's products are designed for a wide range of sectors, such as aerospace, defense, medical, industrial, military, and semiconductor industries. Additionally, Astrodyne TDI offers custom EMI/EMC/RFI filters and power converters tailored to specific applications. Established in 1994 and headquartered in Mansfield, Massachusetts, the company operates manufacturing facilities in Elizabeth, New Jersey, and Shanghai, China, along with product design centers in Fremont, California; Elizabeth, New Jersey; and Taipei, Taiwan. Astrodyne TDI is committed to providing innovative power technologies and solutions to meet the diverse needs of its global customer base.

Spherics develops proprietary bioadhesive encapsulation technologies to improve the oral absorption of small molecule drugs.

BioXell was founded in 2002 as a spinout of Roche Milano Ricerche, a leading biomedical research institute created ten years earlier that focused on chronic inflammatory disease and autoimmunity. The idea to create BioXell originated with Francesco Sinigaglia, founder and director of the Milan-based research institute, following a scientific career path that took him to the University College in London, the Basel Institute of Immunology and the Hoffmann-La Roche research units in Basel. Dr. Sinigaglia, former CEO, approached Roche with his challenging project and a year later BioXell was spun off, with $22m invested by MPM Capital, Index Ventures and Life Science Partners.

Evotec Neurosciences GmbH is a biotechnology company focused on the discovery and development of small molecule drugs aimed at treating Alzheimer's disease and other neurological disorders. Through its research initiatives, the company seeks to create innovative therapeutics that address significant unmet medical needs in the field of neuroscience.

Momenta Pharmaceuticals, Inc. is a biotechnology company headquartered in Cambridge, Massachusetts, that focuses on the discovery and development of innovative therapeutics for rare immune-mediated diseases. The company's product pipeline includes novel therapeutics such as M281, a fully-human monoclonal antibody targeting the neonatal Fc receptor to reduce circulating IgG antibodies; M254, aimed at treating inflammatory diseases; and M230, a recombinant trivalent IgG1 Fc multimer designed for enhanced therapeutic activity. Additionally, Momenta has developed complex generic products, including M-Enoxaparin, a generic version of Lovenox, and M356, a generic of Copaxone for multiple sclerosis. Momenta also has biosimilar programs, including M923, a biosimilar of HUMIRA, and M710, a biosimilar of EYLEA for various eye conditions. Despite previously pursuing the generics and biosimilars market, the company shifted its focus to innovative drug development, with several promising candidates in the pipeline for autoimmune diseases. Momenta was founded in 2001 and operates as a subsidiary of Johnson & Johnson.

Xention Limited is a biopharmaceutical company based in Cambridge, United Kingdom, that focuses on discovering and developing innovative ion channel-modulating drugs. Founded in 2002, the company aims to address significant unmet medical needs by creating therapies for conditions such as atrial fibrillation, overactive bladder, pain, and autoimmune diseases. Xention develops drug candidates that target two novel yet well-characterized ion channels, striving to produce breakthrough therapies that enhance treatment options in these areas. The company, originally known as Xention Discovery Ltd., rebranded to Xention Limited in October 2006.

Momenta Pharmaceuticals, Inc. is a biotechnology company headquartered in Cambridge, Massachusetts, that focuses on the discovery and development of innovative therapeutics for rare immune-mediated diseases. The company's product pipeline includes novel therapeutics such as M281, a fully-human monoclonal antibody targeting the neonatal Fc receptor to reduce circulating IgG antibodies; M254, aimed at treating inflammatory diseases; and M230, a recombinant trivalent IgG1 Fc multimer designed for enhanced therapeutic activity. Additionally, Momenta has developed complex generic products, including M-Enoxaparin, a generic version of Lovenox, and M356, a generic of Copaxone for multiple sclerosis. Momenta also has biosimilar programs, including M923, a biosimilar of HUMIRA, and M710, a biosimilar of EYLEA for various eye conditions. Despite previously pursuing the generics and biosimilars market, the company shifted its focus to innovative drug development, with several promising candidates in the pipeline for autoimmune diseases. Momenta was founded in 2001 and operates as a subsidiary of Johnson & Johnson.

Oxxon Therapeutics™ (Oxxon) is a company developing the next generation of innovative antigen-specific immunotherapies to treat patients with chronic infectious diseases and cancer. To date, the company has built an initial pipeline through its patented Hi-8™ PrimeBoost immunotherapy platform, an approach that allows the rapid development of products to selectively stimulate and enhance potent immune responses against disease. The company has successfully completed phase II clinical programmes in melanoma and hepatitis B and has a third development programme underway in HIV. In addition, the company intends to leverage its enabling platform through partnerships with companies developing therapeutic and preventative vaccine products.

Avantium is a Dutch technology company specializing in advanced high-throughput research and development for energy, chemicals, and pharmaceutical industries. Headquartered in Amsterdam with state-of-the-art laboratories, Avantium's proprietary technology accelerates product and process innovation while reducing costs. With over 70 global clients, including industry leaders, Avantium has proven its technology's validity and commercial viability. The company focuses on developing new biofuels, bio-based chemicals, and novel crystal forms of marketed drugs under patent. Its team comprises highly educated professionals in catalysis, crystallography, organic chemistry, engineering, statistics, cheminformatics, and software development, collaborating closely with partner R&D organizations to drive innovation.

BioXell was founded in 2002 as a spinout of Roche Milano Ricerche, a leading biomedical research institute created ten years earlier that focused on chronic inflammatory disease and autoimmunity. The idea to create BioXell originated with Francesco Sinigaglia, founder and director of the Milan-based research institute, following a scientific career path that took him to the University College in London, the Basel Institute of Immunology and the Hoffmann-La Roche research units in Basel. Dr. Sinigaglia, former CEO, approached Roche with his challenging project and a year later BioXell was spun off, with $22m invested by MPM Capital, Index Ventures and Life Science Partners.

De Novo Pharmaceuticals is an emerging computational drug design company. De Novo Pharmaceuticals uses its proprietary computational software for drug design to create novel, patentable lead molecules as candidates for drug development. De Novo's proprietary algorithms can convert information from structural genomics and medicinal chemistry rapidly into new chemical designs, maximising value within a pharmaceutical partner's research portfolio. De Novo's drug discovery partners include British Biotechnology, Aventis Pharmaceuticals and NV Organon.